HIV vaccine


Also found in: Wikipedia.

HIV vaccine

AIDS As of mid-2005, there is no viable anti-HIV vaccine. See AIDS.
Mentioned in ?
References in periodicals archive ?
Researchers from Scripps Research Institute hope to reduce the number of people contracting the virus with a new HIV vaccine. The team said they were able to block the "death star" strain that has been preventing scientists from creating an effective treatment for HIV.A
GeoVax Labs announced that Harriet Robinson, PhD, CSO Emeritus and Director of the Company's HIV Vaccine program, delivered an oral presentation entitled, Protein-Supplemented DNA/MVA Vaccines: Preclinical Immunogenicity and Protection for Transmitted/Founder and CD4-induced gp120 Proteins, during the 10th International AIDS Society Conference.
National Institutes of Health (NIH) and Janssen Pharmaceutical Companies of Johnson and Johnson announced Monday a plan to carry out an HIV vaccine efficacy trial in North America, South America and Europe.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the HIV Vaccine Trials Network (HVTN) based at the Fred Hutchinson Cancer Research Center, and the U.S.
Summary: Washington D.C [U.S.A], May 10: Researchers have identified a new HIV vaccine delivery strategy, which provides small doses over series of days leading to stronger immune response than when the same vaccine is given all at once.
Summary: TEHRAN (FNA)- A new candidate HIV vaccine surmounts technical hurdles that stymied previous vaccine efforts, and stimulates a powerful anti-HIV antibody response in animal tests.
While an HIV vaccine would be a game changer, it would be only one of a diverse range of tools needed to contain one of mankind's deadliest pandemics.
KARACHI -- An HIV vaccine that has the potential to protect people around the world from the virus has shown promising results.
"The challenges in the development of an HIV vaccine are unprecedented, and the ability to induce HIV-specific immune responses does not necessarily indicate that a vaccine will protect humans from HIV infection," he added.
A HIV vaccine could be within grasp after a breakthrough in a treatment's first human trial.
[7] Simultaneous licensure of an efficacious prophylactic HIV vaccine for both adults and adolescents is important; however, testing of a candidate vaccine in adolescent populations is likely to be required for age-specific licensure.
The start of the new trial involving 2,600 women in southern Africa means that for the first time in more than a decade there are now two big HIV vaccine clinical trials taking place at the same time.